ArticleClinicoEconomics and outcomes research : CEOR2025

Healthcare Resource Utilization and Cost Comparison Between Palbociclib, Abemaciclib, and Ribociclib Among Patients with HR+/HER2- Metastatic Breast Cancer.

Timothy J Pluard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.